Podcast
Turning Poop to Gold: Jenny Yang, Outpost Bio
Turning Poop to Gold: Jenny Yang, Outpost Bio


Jenny Yang's Live Interview on Ventures- Discussing how the poop science, AI, and the $3.5M pre-seed leading to Outpost's success.
Jenny Yang's Live Interview on Ventures- Discussing how the poop science, AI, and the $3.5M pre-seed leading to Outpost's success.
Outpost Bio Co-Founder and CEO Jenny Yang joined Raj to talk about Outpost’s mission to make human microbiology computable—and why the microbiome could be a critical missing layer in understanding how people respond differently to drugs, food, and other interventions.
The conversation covers:
Why differences in the gut microbiome may help explain why two people with the same genetics and the same medication can have very different outcomes
How Outpost combines purpose-built biological datasets with AI models to predict how microbial communities interact with drugs, food, and other molecules
How a better understanding of the microbiome could push personalized medicine beyond human genomics alone
How pharma, biotech, and consumer R&D teams can use microbiome data to understand efficacy, side effects, and differences across populations
Why Jenny sees advances in biological measurement and AI as an opportunity to tackle persistent challenges in drug development and human health
Outpost Bio Co-Founder and CEO Jenny Yang joined Raj to talk about Outpost’s mission to make human microbiology computable—and why the microbiome could be a critical missing layer in understanding how people respond differently to drugs, food, and other interventions.
The conversation covers:
Why differences in the gut microbiome may help explain why two people with the same genetics and the same medication can have very different outcomes
How Outpost combines purpose-built biological datasets with AI models to predict how microbial communities interact with drugs, food, and other molecules
How a better understanding of the microbiome could push personalized medicine beyond human genomics alone
How pharma, biotech, and consumer R&D teams can use microbiome data to understand efficacy, side effects, and differences across populations
Why Jenny sees advances in biological measurement and AI as an opportunity to tackle persistent challenges in drug development and human health
Related articles
Legal Pages
©OUTPOST BIO 2026
BAKED BY THE SOURDOUGH
©OUTPOST BIO 2026
BAKED BY THE SOURDOUGH


